A comparison of subcutaneous versus intramuscular DMPA as a choice of contraceptive method to see the difference in efficacy of dmpa in both modes of injections among reproductive wome
Phase 4
- Registration Number
- CTRI/2024/07/070627
- Lead Sponsor
- Dr neha kumari
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Women giving informed consent for receiving DMPA and ready to follow up visits every 3 months and are falling in category 1 or 2 of WHO Medical Eligibility Criteria for injection DMPA in following phases;
a.Post menstrual
b.Post abortal
c.6 weeks post delivery.
Exclusion Criteria
Women with prior history of menstrual irregularities.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (1) Percentage of women willing to continue subcutaneous Depot medroxyprogesterone acetate (DMPA) as contraceptive method. <br/ ><br>(2) Percentage of women willing to continue intramuscular DMPA as contraceptive method <br/ ><br> <br/ ><br>Timepoint: 12 months
- Secondary Outcome Measures
Name Time Method (1) Percentage of women having side effects with subcutaneous DMPA. <br/ ><br>(2) Percentage of women having side effects with intramuscular DMPA. <br/ ><br> <br/ ><br> <br/ ><br>Timepoint: 12 months